Randomised Controlled TrialtaVNS

Transcutaneous auricular vagus nerve stimulation to treat narcolepsy type 1 (TARGET-NT1): A two-arm, randomised, sham-controlled trial

Pan Y, Zhang Y, Xu Z, Wei Z, Pan R, Hu G, Wang X, Yang L, Wu D, Zhang X, et al.

Neurotherapeutics · 2025

Key finding

In a double-blind, sham-controlled RCT (TARGET-NT1), taVNS as add-on therapy significantly improved daytime sleepiness and cataplexy symptoms in narcolepsy type 1.

Auto-extracted · verification pendingHow we verify

Condition
Sleep
Stimulation
taVNS
Evidence tier
Randomised Controlled Trial
Participants
View on DOI

Share this study

Download the citation card as a PNG, or copy a link to this page.

Cite this study

Pan, Y., Zhang, Y., Xu, Z., Wei, Z., Pan, R., Hu, G., Wang, X., Yang, L., Wu, D., Zhang, X., Wen, X., Qu, S., Li, C., Zhu, Z., Gao, Y., Shi, X., Zhu, Y., Wu, K., Wang, D., & Liu, Y. (2025). Transcutaneous auricular vagus nerve stimulation to treat narcolepsy type 1 (TARGET-NT1): A two-arm, randomised, sham-controlled trial. Neurotherapeutics, 22(4), e00604. https://doi.org/10.1016/j.neurot.2025.e00604

Related studies in Sleep

Summary by Vagus Research. Always consult the primary source for the authoritative record.

Stay Current with the Research

Join researchers and practitioners exploring the science of vagus nerve stimulation. Receive curated research summaries and evidence updates.

No spam. Unsubscribe at any time. We respect your privacy.